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Abstract
The presence of relatively high levels of cellular protein contamination in density-purified virion
preparations is a confounding factor in biochemical analyses of HIV and SIV produced from
hematopoietic cells. A major source of this contamination is from vesicles, either microvesicles or
exosomes, that have similar physical properties as virions. Thus, these particles can not be removed
by size or density fractionation. Although virions and vesicles have similar cellular protein
compositions, CD45 is excluded from HIV-1 yet is present in vesicles produced from
hematopoietic cells. By exploiting this finding, we have developed a CD45 immunoaffinity depletion
procedure that removes vesicles from HIV-1 preparations. While this approach has been
successfully applied to virion preparations from several different cell types, some groups have
concluded that "exosomes" from certain T cell lines, specifically Jurkat, do not contain CD45. If this
interpretation is correct, then these vesicles could not be removed by CD45 immunoaffinity
depletion. Here we show that dense vesicles produced by Jurkat and SupT1/CCR5 cells contain
CD45 and are efficiently removed from preparations by CD45-immunoaffinity depletion. Also,
contaminating cellular proteins were removed from virion preparations produced by these lines.
Previously, the absence of CD45 from both "exosomes" and virions has been used to support the
so called Trojan exosome hypothesis, namely that HIV-1 is simply an exosome containing viral
material. The presence of CD45 on vesicles, including exosomes, and its absence on virions argues
against a specialized budding pathway that is shared by both exosomes and HIV-1.
Findings
HIV-1 incorporates cellular proteins from the host cell
during assembly and budding [1]. These proteins can pro-
vide important information about virus-cell interactions,
yet biochemical analyses are greatly hindered by the pres-
ence of protein-laden vesicles in virion preparations, espe-
cially those produced by hematopoeitic cells. Because
these vesicles co-purify with virions due to their similar
size and density [2,3], they cannot be purified from viri-
ons using differences in physical properties alone. Vesicles
can come from two sources: microvesicles that bud from
the plasma membrane [4,5] and exosomes that form in
late endosomal bodies and are released by exocytosis
[6,7]. Therefore, we use the term vesicles to indicate the
potential presence of both types of particles.
CD45 is abundantly expressed on the surface of hemato-
poeitic cells and their vesicles [8-11]. Nevertheless, CD45
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protein is excluded from virions [9,11-13]. We have
exploited this differential incorporation of CD45 to
remove vesicles from virions by immunoaffinity deple-
tion using anti-CD45-conjugated paramagnetic
microbeads. While this technique has been used to pro-
duce high-purity virions for both biochemical and virus-
cell interaction studies [12-14], it requires that vesicles
contain sufficient amounts of CD45 for removal by the
anti-CD45 beads. While we have consistently observed
this in our experiments [12-14], two papers report that
"exosomes" produced by Jurkat T cells, i.e. dense particles
isolated from culture supernatants, do not contain CD45
[15,16], apparently excluding this protein during vesicle
formation. If this were true and these "exosomes" are a
distinct class of vesicle that do not contain CD45, then
immunoaffinity depletion would not be able to remove
vesicles from virus preparations isolated from cells that
reputedly produce mostly "exosomes", e.g. Jurkat cells
[15,16].
To determine whether these vesicles can be removed, we
produced cell culture supernatants from uninfected Jurkat
(gift of Kendall Smith, Cornell University, Ithaca, NY) and
SupT1/CCR5 (gift of James Hoxie, University of Pennsyl-
vania, Philadelphia, PA [17]) cells, two cell lines com-
monly used for the production of HIV-1. To confirm the
Jurkat results we obtained the reference Jurkat E6-1 cell
line [18] from the NIAID AIDS Reference Program. Vesicle
preparations were produced from 50 mls of uninfected
cell culture supernatants (material produced from a cul-
ture of 8 × 105 cells per ml for 48 hr) using the same 20%
sucrose centrifugation procedure as used for virion prepa-
rations [19]. Half of the vesicle preparations (equivalent
to 25 ml of supernatant) were subjected to CD45 immu-
noaffinity depletion. Equal amounts (by initial superna-
tant volume) of both depleted and untreated vesicles were
examined by immunoblotting and SDS-PAGE analysis as
previously described [20]. Immunoblotting with a pan-
specific CD45 antibody did not detect any CD45 signal in
the depleted samples, while there was a strong signal in
both the untreated Jurkat and SupT1/CCR5 samples (Fig-
ure 1A). A somewhat weaker signal was detected in the
untreated Jurkat E6-1 sample, presumably due to less
CD45 on the vesicles. Nevertheless, this signal was also
removed by depletion. The bead fractions for each sample
showed an intense signal from the captured CD45.
Actin is an abundant component of vesicles and can be
used as a marker for vesicular contamination in the
absence of virus [21]. To assay for the presence of this pro-
tein, the blot was stripped of the CD45 signal and exposed
to a pan-actin antibody. The results showed that, similar
to the CD45 finding, actin was not detectable in the
depleted samples, but was present as an intense band in
all three untreated samples as well as the bead fractions
(Figure 1A). Based on the intensities of the actin bands
(Figure 1A), equal amounts of material were loaded for
each vesicle preparation, confirming the lower levels of
CD45 present on the Jurkat E6-1 vesicles. Yet, even this
lower level of CD45 was sufficient for removal vesicles
from the preparation.
To examine their overall protein composition, the sam-
ples were examined by SDS-PAGE gel electrophoresis. The
depleted preparations contained only a few faint bands
(data not shown), mostly corresponding to bovine serum
proteins such as albumin, which are carried-over from the
culture medium during the initial density preparation. To
remove these medium-based contaminants and allow for
a clearer assessment of protein content, vesicles were iso-
lated from three separate harvests of SupT1/CCR5 and Jur-
kat E6-1 cell supernatants by two sequential density
centrifugation steps. SDS-PAGE gel analysis of these prep-
arations after CD45-depletion did not detect any protein
(representative data in Figure 1A) except for faint histone
bands in the SupT1/CCR5 samples, likely from DNA com-
plexes that co-purify due to their density (>1.5 g/ml) [22].
In contrast, the untreated vesicle samples contained (Fig-
ure 1A) a wide range of proteins including actin and his-
tones but no BSA. An additional set of vesicle preparations
were produced from 90 ml of culture supernatants and
half of each was CD45-depleted. The proteins in the
resulting matched samples were then quantified by the
Bio-Rad DC kit (Hercules, CA) using a BSA standard.
Results of duplicate determinations from the three inde-
pendent isolations showed that CD45 depletion effec-
tively removed the vesicular proteins (95%, SD ± 3%, n =
7 from Jurkat E6-1 and 96% SD ± 2%, n = 6 from SupT1/
CCR5). These results and those above demonstrate that
CD45 immunoaffinity depletion removes the vesicle-
associated proteins produced by these cells.
The purpose of CD45 immunoaffinity depletion is to
remove contaminants from virus preparations. To dem-
onstrate this on virions, we infected both SupT1/CCR5
and Jurkat E6-1 cell lines with a stock of HIV-1NL4-3 (MOI
~0.1). Following two washes, cells were cultured in
medium for 1 week and then virus was prepared from a 2-
day harvest by density centrifugation. Equal amounts of
HIV-1 by initial supernatant volume from the infected
SupT1/CCR5 (0.8 μg CA) and Jurkat E6-1 (2.2 μg CA) cell
cultures were CD45 immunoaffinity depleted. Depleted
and untreated samples were examined by CD45 immuno-
blot analysis. The results showed that depletion removed
all detectable CD45 from the treated samples (Figure 1B).
Staining the blot for actin revealed that nearly all of the
actin was removed from the virus preparations. Some
actin did persist in the Jurkat E6-1 sample, consistent with
some actin remaining inside the virion as previously
observed [21].Retrovirology 2008, 5:64 http://www.retrovirology.com/content/5/1/64
Page 3 of 5
(page number not for citation purposes)
Immunoblots and SDS-PAGE gels of vesicles and virion samples Figure 1
Immunoblots and SDS-PAGE gels of vesicles and virion samples. Immunoblots and SDS-PAGE gels of vesicle preparations (A) or virion 
preparations (B) (equal amounts by volume) isolated from cell cultures are presented. The samples are identified above their respective 
lanes. Antibody or antiserum used is indicated. Pertinent bands are identified at right of the blots. Cellular proteins reduced in depleted 
virion preparations are denoted in panel B with a dot at right. Cells were cultured in RPMI 1640 media with 2 mM L-glutamine, 100 U per 
ml penicillin, 100 μg per ml streptomycin and 10% vol/vol fetal bovine serum. CD45 immunoaffinity depletion was carried out using 100 μl 
of anti-CD45 paramagnetic microbeads (cat # 130-045-801, Miltenyi Biotec Inc.) that were washed in PBS and recovered by a magnetic 
separator (model MPC-S, Invitrogen, Inc.) twice before use. After an hour incubation at room temperature, the suspension was placed in 
a magnetic separator overnight at 4°C to capture the beads. The supernatant carefully removed from the beads and analyzed. Pan-specific 
CD45 antibody was obtained from BD-Transduction Laboratories, San Diego, CA, cat # 610266, Clone 69, IgG1. The pan-actin antibody 
was obtained from Amersham Biosciences, Arlington, IL, cat # N.350. CA antiserum was from the AIDS and Cancer Virus Program, NCI-
Frederick, Goat # 81. SDS-PAGE gels were stained with by Coomassie brilliant blue to visualize proteins.
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The presence of virus was revealed by stripping and stain-
ing the blot with capsid (CA) antiserum: the treated sam-
ples had somewhat less intense staining CA bands than
the untreated material. Similarly, the bead fractions had
CA signal, though at a lower intensity than either the
treated or untreated samples, indicating that some CA was
removed by depletion, likely due to virus/vesicle aggre-
gates that are formed by pelleting during purification [12].
This artifact is not observed when supernatants are
depleted before centrifugation [12,13].
The SDS-PAGE gel results showed that the HIV-1 prepara-
tions from the SupT1/CCR5 cells contained a large
amount of cellular proteins compared with the Jurkat E6-
1 preparation (Figure 1B). CD45 immunoaffinity deple-
tion markedly removed the contamination from the
SupT1/CCR5 preparation, demonstrating the efficacy of
the procedure. Because the Jurkat E6-1 preparation was
relatively free from contamination, the removal of vesicles
was less dramatic. However, the intensities of several cel-
lular protein bands, including actin (labeled with dots in
Figure 1B) decreased after depletion. Together with the
CD45 and actin blots, these results show that the CD45
immunoaffinity procedure can remove cellular proteins
from these virion preparations.
Overall, our results show that vesicles isolated from Jurkat
and SupT1/CCR5 cells, whether microvesicles or exo-
somes, contain sufficient amounts of CD45 to allow for
removal by anti-CD45 paramagnetic microbeads. This
finding is in contrast to the previous reports that con-
cluded that T cell "exosomes" from uninfected cells do not
contain CD45 [15,16]. Despite procedural differences,
our preparations should have contained at least some, if
not all of the vesicular species that the other groups exam-
ined. Furthermore, CD45 has been detected in vesicle
preparations from monocyte-derived macrophages [9], a
cell type thought to produce mostly exosomes [23], and
these particles can be effectively removed by CD45 deple-
tion [13]. A more plausible explanation for the difference
is that we use a CD45 antibody that recognizes an epitope
in the cytoplasmic domain that is shared among all forms
of CD45 for detection, while the other groups used anti-
bodies that recognize its variable extracellular portion
[15,16], thus may not detect all forms of CD45.
Booth et al. have proposed that HIV-1 relies extensively, if
not exclusively, on an exosome budding pathway for
release from the cell that is distinct from that of other par-
ticles [16]. This model is part of the authors' Trojan exo-
some hypothesis [24] which posits that HIV-1 is simply an
exosome that contains HIV-1 components. Part of the
support for HIV-1 using an exosome budding pathway
was the apparent absence of CD45 from both virions and
exosomes, implying a common CD45-free budding
mechanism [16]. Thus, our data provided here do not
support this type of a distinct, specialized and shared
release pathway for HIV-1 and exosomes.
While CD45 immunoaffinity depletion can remove con-
taminating vesicles from preparations, some rare particles
might remain. Formally, productive infection itself might
induce the production of vesicles that lack CD45, though
this has not been observed. It is important to note that,
absolute biochemical purity of virion preparations may
not be practically attainable and analyses should be eval-
uated with this important caveat in mind.
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